NASDAQ •
Healthcare •
Biotechnology •
Quote as of 08/26/2026 16:00
Company Profile
IndustryBiotechnology
SectorHealthcare
ExchangeNASDAQ
Market Capitalization45.82 mln
Float131 mln
Earnings Date11/17/2026
Piotroski F-Score
4
/ 9
Borderline
1-Year Forecast
2.01
Transformational upside
Relative Strength
13
/ 100
Significantly lagging
Debt / Equity
0.04
Debt-free
ROE
-68.74
Deeply negative
Dividend Yield
0.00%
No dividend
Business Description
Mereo BioPharma Group is a UK-based medical company focused on developing treatments for rare and serious diseases, operating across both the United Kingdom and the United States. Founded in 2015 and headquartered in London, the company is advancing a range of drug candidates targeting conditions such as brittle bone disease, lung disease, certain cancers, and hormonal disorders. Several of these treatments are currently in clinical trials, with others being developed through partnerships with companies including AstraZeneca, Feng Biosciences, and ReproNovo.
